Alvotech Reports Robust Q1 2025 Growth and Strategic Expansions

The latest update is out from Alvotech ( (ALVO) ).

On May 7, 2025, Alvotech reported significant financial growth for the first quarter of 2025, with total revenues reaching $132.8 million, a 260% increase from the previous year. The company also announced the launch of SELARSDI, a biosimilar to Stelara, in the U.S., and the acceptance of several Biologics License Applications for other biosimilars. Alvotech’s acquisition of Xbrane’s R&D operations and rights to a biosimilar candidate referencing Cimzia highlights its strategic expansion efforts. The company expects to achieve $600-$700 million in top-line revenue and $200-$280 million in adjusted EBITDA for the full year, reflecting its strengthened market position and operational efficiencies.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Underperform.

Alvotech’s overall stock score is low due to significant financial performance challenges, bearish technical indicators, and poor valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and high financial leverage, highlighting risks of financial instability. Technical analysis confirms a downward trend, with valuation metrics reflecting these underlying issues.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide. The company focuses on creating biosimilars for various therapeutic areas and has a strong presence in major markets including the U.S., Europe, Canada, and Japan.

Average Trading Volume: 127,096

Technical Sentiment Signal: Sell

Current Market Cap: $2.41B

Find detailed analytics on ALVO stock on TipRanks’ Stock Analysis page.